CTLA4 and hepatocellular carcinoma: The IPS, IPS-CTLA4, IPS-PD1-PD-L1- PD-L2, and IPS-PD1-PD-L1-PD-L2-CTLA4 blocker were significantly higher in low-risk group, implying that HCC patients with low-risk score could benefit more from ICI therapy than high-risk patients (Fig. 10C).